Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study to Evaluate Safety and Tolerability After Single Administration of PER-001 Intravitreal Implant in Participants With Diabetic Retinopathy

NCT06003751 is registered in ClinicalTrials.gov with Perfuse Therapeutics, Inc. as lead sponsor.

NCT NCT06003751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study to Evaluate Safety and Tolerability After Single Administration of PER-001 Intravitreal Implant in Participants With Diabetic Retinopathy
Lead sponsor
Perfuse Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 5, 2023
Completion date
December 10, 2025
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy